An Investigation of the Economic Burden of Treatment for Namd/Dme on Treatment Recipients and Caregivers in the US
Author(s)
Tabano D1, Watane A2, Gale R3, Cox O4, Garmo V1, Hill S5, Longworth L5, Oluboyede Y5, Ahmed A1, Patel N6
1Genentech, Inc., South San Francisco, CA, USA, 2Yale School of Medicine, New Haven, CT, USA, 3York Teaching Hospital NHS Foundation Trust, York, UK, 4F. Hoffmann-La Roche, Basel, BS, Switzerland, 5Putnam PHMR Ltd., London, LON, UK, 6Harvard Medical School, Boston, MA, USA
Presentation Documents
OBJECTIVES:
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are conditions which can lead to irreversible vision loss. Intravitreal injection of anti-Vascular Endothelial Growth Factor (VEGF) agents is the standard of care for people with nAMD and DME in the US. We investigated the economic burden of treatment for nAMD and DME on patients and their caregivers.METHODS:
A cross-sectional survey of people with nAMD/DME and caregivers in the US was conducted from September to December 2022. Questions focused on treatments received for nAMD/DME, treatment schedules, and costs associated with visits made to health services to receive (or to accompany someone to receive) treatment.RESULTS:
Data were collected from 75 people with nAMD (n=52), DME (n=20), or both (n=3) and 82 caregivers of people with nAMD (n=34), DME (n=13), or both (n=35). 45 (60%) people were currently receiving, and 54 (66%) were caregivers of people receiving, anti-VEGF treatment. Most patients reported receiving anti-VEGF injections monthly. People received anti-VEGF treatment from an ophthalmologist in hospital (25 [56%]), private clinic (35 [78%]) and another health service settings (16 [36%]). Median (range) of out-of-pocket cost to patients at treatment visits across health service types was $30 ($0-$420). In the previous 6 months, 48 (89%) caregivers of people with nAMD/DME receiving anti-VEGF injections accompanied their care recipient to visits in hospital, 41 (76%) to a private clinic, and 42 (78%) to another health service for anti-VEGF treatment. Median time patients spent attending anti-VEGF treatment visits was 60 minutes (122 minutes for caregivers). Median (range) out-of-pocket costs paid by caregivers for the treatment of their care recipient was $136.67 ($0-$810).CONCLUSIONS:
Anti-VEGF treatment is associated with considerable burden on patients with nAMD/DME and their caregivers. Frequent treatment visits placed a substantial economic burden on patients and caregivers, both financially and on their time.Conference/Value in Health Info
2023-05, ISPOR 2023, Boston, MA, USA
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
EE191
Topic
Economic Evaluation
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin)